AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19463202 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate, 110 mug q.d. for 4 weeks
Number of subjects: 699
Study 19463202 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 699
Study 16501036 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal E2/NETA [175 microg/275 microg]
Number of subjects: 90
Study 16501036 — intervention group
Group type: COMPARATOR
Intervention: Oral E2/NETA [1 mg/0.5 mg]
Number of subjects: 90
Study 16501036 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 15545881 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttherapy scanning on first ablation
Number of subjects: 106
Study 15545881 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttherapy scanning
Number of subjects: 106
Study 10675118 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme based on clinical-practice guideline
Number of subjects: 4192
Study 10675118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 4192
Study 9095401 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (150 mg/kg per day)
Number of subjects: 22
Study 9095401 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (15 mg/kg per day)
Number of subjects: 22
Study 1311650 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpressor dose of angiotensin II (3 ng min‐1 kg‐1 for 15 min)
Number of subjects: 8
Study 1311650 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpressor dose of angiotensin II (3 ng min‐1 kg‐1 for 15 min) during handgrip exercise
Number of subjects: 8
Study 1311650 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressor dose of angiotensin II (13 ng min‐1 kg‐1 for 15 min)
Number of subjects: 8
Study 1311650 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressor dose of angiotensin II (13 ng min‐1 kg‐1 for 15 min) during isometric exercise
Number of subjects: 8
Study 4017672 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (4 mg/kg twice daily for three days)
Number of subjects: 13
Study 4017672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31186395 — intervention group
Group type: EXPERIMENTAL
Intervention: DynaCT+DSA treatment group (27 cases)
Number of subjects: 57
Study 31186395 — intervention group
Group type: COMPARATOR
Intervention: DSA treatment group (30 cases)
Number of subjects: 57
Study 31186395 — intervention group
Group type: EXPERIMENTAL
Intervention: DynaCT+DSA treatment group
Number of subjects: 57
Study 31186395 — intervention group
Group type: COMPARATOR
Intervention: DSA treatment group
Number of subjects: 57
Study 30178733 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective Subjective Memory Complaints (SMCs)
Number of subjects: 560
Study 30178733 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective Subjective Memory Complaints (SMCs)
Number of subjects: 560
Study 30178733 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms and poor quality of life
Number of subjects: 560
Study 30178733 — intervention group
Group type: EXPERIMENTAL
Intervention: PRMQ (Prospective and Retrospective Memory Questionnaire)
Number of subjects: 560
Study 30178733 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported memory problems
Number of subjects: 560
Study 28301177 — intervention group
Group type: EXPERIMENTAL
Intervention: Deontologists in social dilemma games
Number of subjects: 0
Study 28301177 — intervention group
Group type: EXPERIMENTAL
Intervention: Deontologists in public goods games
Number of subjects: 0
Study 28301177 — intervention group
Group type: COMPARATOR
Intervention: Consequentialists in social dilemma games
Number of subjects: 0
Study 28301177 — intervention group
Group type: EXPERIMENTAL
Intervention: Deontologists in trust games
Number of subjects: 0
Study 26254984 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration of pus
Number of subjects: 53
Study 26254984 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 53
Study 23280682 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity Score Matching
Number of subjects: 1292
Study 23280682 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity Score Weighting
Number of subjects: 1292
Study 23280682 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity Score Weighting after excluding extreme observations
Number of subjects: 1292
Study 21565848 — intervention group
Group type: EXPERIMENTAL
Intervention: AC‐RCT participants (579 patients)
Number of subjects: 1242
Study 21565848 — intervention group
Group type: COMPARATOR
Intervention: Non-participants (663 patients)
Number of subjects: 1242
Study 18474494 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r + FPV
Number of subjects: 56
Study 18474494 — intervention group
Group type: COMPARATOR
Intervention: LPV/r or FPV + r
Number of subjects: 56
Study 16634531 — intervention group
Group type: EXPERIMENTAL
Intervention: Contractubex®
Number of subjects: 859
Study 16634531 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 859
Study 12910523 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel (C/P) for 4 cycles (AUC of 6 for carboplatin and 200 mg/m2 for paclitaxel every 21 days)
Number of subjects: 230
Study 12910523 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel (C/P)
Number of subjects: 230
Study 11099872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg per day
Number of subjects: 0
Study 11099872 — intervention group
Group type: COMPARATOR
Intervention: Transdermic 17 beta‐estradiol at 50 microg per day
Number of subjects: 0
Study 9259219 — intervention group
Group type: EXPERIMENTAL
Intervention: Short cognitive behavioural group therapy programme focused on patient education and stress relaxation.
Number of subjects: 0
Study 9259219 — intervention group
Group type: COMPARATOR
Intervention: Control group of untreated patients.
Number of subjects: 0
Study 8318322 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural clonidine 450 micrograms
Number of subjects: 30
Study 8318322 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural clonidine 450 micrograms plus oral yohimbine 16 mg
Number of subjects: 30
Study 8318322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3522003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (6.2 +/- 1.7 micrograms/kg/min)
Number of subjects: 9
Study 3522003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (6.7 +/- 2.5 micrograms/kg/min)
Number of subjects: 9
Study 3522003 — intervention group
Group type: COMPARATOR
Intervention: Comparison of dopamine and dobutamine
Number of subjects: 9
Study 29385644 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-mouth recording (PMR) protocols
Number of subjects: 640
Study 29385644 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PMR protocols
Number of subjects: 640
Study 26846934 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroscopy with or without labral repair
Number of subjects: 80
Study 26846934 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (2 sessions per week for 6 weeks)
Number of subjects: 80
Study 26846934 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (hip arthroscopy and physical therapy)
Number of subjects: 80
Study 25137867 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 90
Study 25137867 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 90
Study 25137867 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic bronchoscope
Number of subjects: 90
Study 23529771 — intervention group
Group type: COMPARATOR
Intervention: Night Float (NF) model
Number of subjects: 43
Study 23529771 — intervention group
Group type: COMPARATOR
Intervention: Q5 model (every fifth night overnight call)
Number of subjects: 43
Study 23529771 — intervention group
Group type: COMPARATOR
Intervention: Q5 model
Number of subjects: 43
Study 23529771 — intervention group
Group type: COMPARATOR
Intervention: NF model
Number of subjects: 43
Study 23529771 — intervention group
Group type: COMPARATOR
Intervention: 2003-compliant model (control)
Number of subjects: 43
Study 20388468 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine interventions
Number of subjects: 0
Study 20388468 — intervention group
Group type: COMPARATOR
Intervention: Pragmatic randomized controlled trial (PRCT)
Number of subjects: 0
Study 17943371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FG)
Number of subjects: 22
Study 17943371 — intervention group
Group type: COMPARATOR
Intervention: Staples (SG)
Number of subjects: 22
Study 16639677 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated ECC circuits (group A)
Number of subjects: 28
Study 16639677 — intervention group
Group type: COMPARATOR
Intervention: Uncoated ECC circuits (group B)
Number of subjects: 28
Study 14583417 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 alfalfa capsules per day)
Number of subjects: 36
Study 14583417 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose kelp (2 kelp capsules and 2 alfalfa capsules per day)
Number of subjects: 36
Study 14583417 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose kelp (4 kelp capsules per day)
Number of subjects: 36
Study 10981244 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 1000
Study 10981244 — intervention group
Group type: COMPARATOR
Intervention: No ACE inhibitors
Number of subjects: 1000
Study 10981244 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors in hypertensive patients
Number of subjects: 1000
Study 10981244 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors in normotensive patients
Number of subjects: 1000
Study 10981244 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors usage over time
Number of subjects: 1000
Study 10981244 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors in patients with adverse renal outcomes
Number of subjects: 1000
Study 7643882 — intervention group
Group type: COMPARATOR
Intervention: Heparin (10,000 IU bolus followed by intravenous infusion for 24 hours and subcutaneous placebo twice daily for three days)
Number of subjects: 1141
Study 7643882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hirudin (40 mg bolus followed by intravenous infusion for 24 hours and subcutaneous placebo twice daily for three days)
Number of subjects: 1141
Study 7643882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and subcutaneous hirudin (40 mg bolus followed by intravenous infusion for 24 hours and subcutaneous hirudin twice daily for three days)
Number of subjects: 1141
Study 7643882 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (combined group of intravenous and subcutaneous)
Number of subjects: 1141
Study 7643882 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1141
Study 7643882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hirudin
Number of subjects: 1141
Study 7643882 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1141
Study 2539286 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% carbohydrate diet
Number of subjects: 0
Study 2539286 — intervention group
Group type: COMPARATOR
Intervention: 40% carbohydrate diet
Number of subjects: 0
Study 319698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonabsorbable subcuticular sutures
Number of subjects: 17
Study 319698 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable subcuticular sutures
Number of subjects: 17
Study 319698 — intervention group
Group type: COMPARATOR
Intervention: Control (superior and inferior portions of the scar)
Number of subjects: 17
Study 31124299 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi (insulin glargine 100 U and lixisenatide)
Number of subjects: 859
Study 31124299 — intervention group
Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 859
Study 31124299 — intervention group
Group type: COMPARATOR
Intervention: Lixi
Number of subjects: 859
Study 31124299 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 859
Study 27800565 — intervention group
Group type: EXPERIMENTAL
Intervention: Six PA SMS/week
Number of subjects: 80
Study 27800565 — intervention group
Group type: COMPARATOR
Intervention: Standard T4b SMS
Number of subjects: 80
Study 26124653 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 82
Study 26124653 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 82
Study 24244272 — intervention group
Group type: EXPERIMENTAL
Intervention: Online video of diagnosis-specific discharge instructions
Number of subjects: 133
Study 24244272 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 133
Study 20831368 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally delivered doxycycline (8.8% doxycycline gel) as an adjunct to mechanical debridement
Number of subjects: 32
Study 20831368 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement only (control group)
Number of subjects: 32
Study 20831368 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally delivered doxycycline
Number of subjects: 32
Study 18435949 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI hyperemic flow (CTFC<14)
Number of subjects: 3491
Study 18435949 — intervention group
Group type: COMPARATOR
Intervention: Normal flow (CTFC 14 to 28)
Number of subjects: 3491
Study 17152037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephazolin prophylaxis
Number of subjects: 303
Study 17152037 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 303
Study 14614668 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-chloroquine (group 1)
Number of subjects: 123
Study 14614668 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-sulfadoxine-pyrimethamine (group 2)
Number of subjects: 123
Study 10924313 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (n=84)
Number of subjects: 409
Study 10924313 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm (n=325)
Number of subjects: 409
Study 10924313 — intervention group
Group type: EXPERIMENTAL
Intervention: New onset atrial fibrillation (n=30)
Number of subjects: 409
Study 9412078 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrusion products 'Jantar' containing 10% dietary fiber gumarabic
Number of subjects: 0
Study 8458181 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 30
Study 8458181 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg
Number of subjects: 30
Study 8458181 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 30
Study 8458181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3755608 — intervention group
Group type: EXPERIMENTAL
Intervention: CQP201-403 (0.025 mg)
Number of subjects: 6
Study 3755608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 28745520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 51
Study 28745520 — intervention group
Group type: COMPARATOR
Intervention: Attention control (HF self-management education)
Number of subjects: 51
Study 29915869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 60
Study 29915869 — intervention group
Group type: COMPARATOR
Intervention: Diffuser mask (OxyMask)
Number of subjects: 60
Study 27733405 — intervention group
Group type: EXPERIMENTAL
Intervention: No-carbohydrate breakfast
Number of subjects: 45
Study 27733405 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate breakfast
Number of subjects: 45
Study 24246414 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 664
Study 24246414 — intervention group
Group type: COMPARATOR
Intervention: 68 Gy
Number of subjects: 664
Study 22563751 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 110
Study 22563751 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 110
Study 20974324 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of Clopidogrel bisulfate (300 mg on day 1, then 75 mg for 6 days)
Number of subjects: 30
Study 20974324 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference formulation of Clopidogrel bisulfate (300 mg on day 1, then 75 mg for 6 days)
Number of subjects: 30
Study 20974324 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of Clopidogrel bisulfate
Number of subjects: 30
Study 20974324 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference formulation of Clopidogrel bisulfate
Number of subjects: 30
Study 20974324 — intervention group
Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 30
Study 18607941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SNB)
Number of subjects: 35
Study 16045502 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the left M1
Number of subjects: 16
Study 16045502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS of the left M1
Number of subjects: 16
Study 16045502 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 16
Study 11854741 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced duplex scanning using sulphur hexafluoride (SF(6))
Number of subjects: 14
Study 10939028 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day
Number of subjects: 0
Study 10939028 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10 mg/day
Number of subjects: 0
Study 8777116 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered intravenously over 15 seconds to premedicated children with midazolam
Number of subjects: 110
Study 8777116 — intervention group
Group type: COMPARATOR
Intervention: Propofol administered intravenously over 15 seconds to unpremedicated children
Number of subjects: 110
Study 1497159 — intervention group
Group type: EXPERIMENTAL
Intervention: Minidose succinylcholine (0.1 mg/kg) IV
Number of subjects: 46
Study 1497159 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (0.03 mg/kg) IV
Number of subjects: 46
Study 6369006 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 207
Study 6369006 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 207
Study 30368021 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (measured by Fitbit activity)
Number of subjects: 32
Study 30368021 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sleep quality (PSQI > 5)
Number of subjects: 32
Study 30148646 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week intervention program to improve landing techniques through strength and plyometric training 3 times a week
Number of subjects: 40
Study 30148646 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week intervention program
Number of subjects: 40
Study 30148646 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular training only)
Number of subjects: 40
Study 27053769 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 0
Study 27053769 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin (AVP)
Number of subjects: 0
Study 27053769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24222194 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 991
Study 24222194 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine plus lapatinib
Number of subjects: 991
Study 22587345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 150 mg
Number of subjects: 3
Study 22587345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 3
Study 22587345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Number of subjects: 3
Study 22587345 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 1-2 mg
Number of subjects: 3
Study 20979470 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 5059
Study 20979470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5059
Study 19334373 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ hemopoietic precursor and stem cells (HPC) in celiac patients (Group B)
Number of subjects: 28
Study 19334373 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A) of healthy subjects
Number of subjects: 28
Study 19334373 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac patients (Group B)
Number of subjects: 28
Study 16043939 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1: All antihypertensive agents given once a day in the morning
Number of subjects: 15
Study 16043939 — intervention group
Group type: COMPARATOR
Intervention: Regimen 2: All antihypertensive agents given in the morning, except the CCB which was given at 4:00 pm
Number of subjects: 15
Study 11812685 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based aprotinin dosing schedule
Number of subjects: 40
Study 11812685 — intervention group
Group type: COMPARATOR
Intervention: Full-dose aprotinin regimen
Number of subjects: 40
Study 10520404 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/CPA (2 mg cyproterone acetate and 0.035 mg ethinyloestradiol)
Number of subjects: 890
Study 7582304 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 26
Study 7582304 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary oxygen
Number of subjects: 26
Study 7582304 — intervention group
Group type: COMPARATOR
Intervention: Domiciliary air
Number of subjects: 26
Study 1936012 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 mg t.i.d.
Number of subjects: 10
Study 1936012 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine 8 mg t.i.d.
Number of subjects: 10
Study 7423136 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphyllin retard (theophylline slow‐releasing coated tablets)
Number of subjects: 16
Study 7423136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31819405 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine 300 mg twice daily (n=126)
Number of subjects: 254